Evidence map›Paper›PMID 36183085›Full record

ArticleBMC medical research methodology2022

Group sequential designs in pragmatic trials: feasibility and assessment of utility using data from a number of recent surgical RCTs.

Nick R Parsons, Nigel Stallard, Helen Parsons, Aminul Haque, Martin Underwood, James Mason, Iftekhar Khan, Matthew L Costa, Damian R Griffin, James Griffin and 5 more

Abstract read
In one paragraph

Article in BMC medical research methodology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nick R ParsonsStatistics and Epidemiology Unit, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK. nick.parsons@warwick.co.uk.
Nigel StallardStatistics and Epidemiology Unit, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
Helen ParsonsWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
Aminul HaqueWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
Martin UnderwoodWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
James MasonWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
Iftekhar KhanWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
Matthew L CostaNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, OX3 7LD, Oxford, UK.
Damian R GriffinWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
James GriffinWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.
David J BeardNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, OX3 7LD, Oxford, UK.
Jonathan A CookCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, OX3 7LD, Oxford, UK.
Loretta DaviesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, OX3 7LD, Oxford, UK.
Jemma HudsonHealth Services Research Unit (HSRU), University of Aberdeen, AB25 2ZD, Aberdeen, UK.
Andrew MetcalfeWarwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK.

Funding

Chief Scientist Office HSRU1Department of HealthMedical Research Council G1001344
6 · The paper itself

Abstract

backgroundAssessing the long term effects of many surgical interventions tested in pragmatic RCTs may require extended periods of participant follow-up to assess effectiveness and use patient-reported outcomes that require large sample sizes. Consequently the RCTs are often perceived as being expensive and time-consuming, particularly if the results show the test intervention is not effective. Adaptive, and particularly group sequential, designs have great potential to improve the efficiency and cost of testing new and existing surgical interventions. As a means to assess the potential utility of group sequential designs, we re-analyse data from a number of recent high-profile RCTs and assess whether using such a design would have caused the trial to stop early.

methodsMany pragmatic RCTs monitor participants at a number of occasions (e.g. at 6, 12 and 24 months after surgery) during follow-up as a means to assess recovery and also to keep participants engaged with the trial process. Conventionally one of the outcomes is selected as the primary (final) outcome, for clinical reasons, with others designated as either early or late outcomes. In such settings, novel group sequential designs that use data from not only the final outcome but also from early outcomes at interim analyses can be used to inform stopping decisions. We describe data from seven recent surgical RCTs (WAT, DRAFFT, WOLLF, FASHION, CSAW, FIXDT, TOPKAT), and outline possible group sequential designs that could plausibly have been proposed at the design stage. We then simulate how these group sequential designs could have proceeded, by using the observed data and dates to replicate how information could have accumulated and decisions been made for each RCT.

resultsThe results of the simulated group sequential designs showed that for two of the RCTs it was highly likely that they would have stopped for futility at interim analyses, potentially saving considerable time (15 and 23 months) and costs and avoiding patients being exposed to interventions that were either ineffective or no better than standard care. We discuss the characteristics of RCTs that are important in order to use the methodology we describe, particularly the value of early outcomes and the window of opportunity when early stopping decisions can be made and how it is related to the length of recruitment period and follow-up.

conclusionsThe results for five of the RCTs tested showed that group sequential designs using early outcome data would have been feasible and likely to provide designs that were at least as efficient, and possibly more efficient, than the original fixed sample size designs. In general, the amount of information provided by the early outcomes was surprisingly large, due to the strength of correlations with the primary outcome. This suggests that the methods described here are likely to provide benefits more generally across the range of surgical trials and more widely in other application areas where trial designs, outcomes and follow-up patterns are structured and behave similarly.

Indexed as

Medical FutilityRecordsData CollectionFeasibility StudiesHumansSample SizeAdaptive designsEarly outcomesInterim analysisRandomized controlled trialsSurgery

Identifiers

PMID36183085
PMCPMC9526271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.